Searchable abstracts of presentations at key conferences in endocrinology

ea0038p428 | Steroids | SFEBES2015

Complications of CAH in pregnancy

Archer Natasha , Roy Chandrima , Levy Miles

Case: A 32 year old with known classical 21 hydroxylase deficiency was planning her first pregnancy. She had a history of clitoral reduction and vaginal reconstructive surgery as a baby. Pre-conception control on prednisone and fludrocortisone was good: 17(OH) progesterone 8.3 nmol/l, androstenedione 9.8 nmol/l (0.7–10.8), testosterone 3.0 nmol/l (0.2–3). EUA showed a small vaginal opening and she was given vaginal dilators. She conceived successfully and was counsel...

ea0070aep657 | Pituitary and Neuroendocrinology | ECE2020

The impact of variations in laboratory measurements of IGF-1 and random growth hormone on the classification of acromegaly disease activity status: Lessons from the UK Acromegaly Register Reference Laboratory

Bashir Bilal , Adam Safwaan , Monaghan Philip , Plummer Zoe , Archer Natasha , Ayuk John , Trainer Peter

Background: The UK Acromegaly Register contains data for 2700 patients. IGF-1 and random growth hormone (GH) measurements are used for disease monitoring. The registry reference laboratory (RRL) uses the Immunodiagnostic systems (IDS)-iSYS immunoassay platform for GH and IGF-1. The RRL uses age- and sex-specific reference ranges for IGF-1. We compared IGF-1 and GH results fromlocal laboratories to those of the RRL (pre-defined as the Gold standard) to determine the extent of d...

ea0077p81 | Neuroendocrinology and Pituitary | SFEBES2021

Is gigantism different from acromegaly in terms of causes of death, comorbidities and treatment? A preliminary retrospective study of 156 UK giants

Kaniuka-Jakubowska Sonia , Abeyaratne Dayakshi , Pal Aparna , Plummer Zoe , Archer Natasha , Ayuk John , Kaszubowski Mariusz , Wass John , Korbonits Marta

Introduction: Although acromegaly and pituitary gigantism have the same pathological cause, they have different disease characteristics.Aim: To study tumour size, treatment course and the most common comorbidities in a population with young-onset acromegaly.Materials and Methods: UK Acromegaly Register (UKAR, 22 centres, 1997-2017) retrospective analysis, enriched with patients from the FIPA-consortium. We defined gigantism as diag...

ea0077op3.1 | Reproductive and Neuroendocrinology | SFEBES2021

Discordant growth hormone and insulin like growth factor-1 values are associated with an increased mortality over concordant normal values in patients treated for acromegaly

Abeyaratne Dayakshi , Kaniuka-Jakubowska Sonia , Plummer Zoe , Archer Natasha , Lakmal Fonseka Chathuranga , Ayuk John , Peter James , McNally Richard , Michael Orme Stephen , Rees Aled , Pal Aparna , Wass John

Background: Growth hormone (GH) and Insulin like growth factor 1 (IGF-1) discordance in patients with acromegaly is a well-recognised phenomenon. It is unclear whether this is associated with increased mortality and morbidity compared to patients with concordant normal results.Methodology: A retrospective study was conducted on the United Kingdom Acromegaly Registry (UKAR). A comparison of mortality and morbidity was performed among four groups categoris...

ea0044oc3.3 | Thyroid and Neoplasia | SFEBES2016

Post-Radioiodine Graves’ Management: The Pragma-Study

Perros Petros , Dayan Colin , Vaidya Bijay , Williams Graham , Lazarus John H , Hickey Janis , Willis Debbie , Archer Natasha , Franklyn Jayne , Basu Ansu

Introduction: Radioiodine (RI) is a safe and effective treatment for Graves’ disease. In the months following RI different strategies are used to gain control of thyroid status, although there is no evidence base as to the optimal approach.Objectives: To compare the incidence of dysthyroidism post-RI between three principal management strategies employed by clinicians.Study design and methods: Retrospective, observational, mul...